AnaptysBio, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 128.72 million compared to USD 57.8 million a year ago. Basic loss per share from continuing operations was USD 4.57 compared to USD 2.11 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.95 USD | -4.24% | -5.19% | +11.81% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.81% | 654M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-3.99% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022